[go: up one dir, main page]

HK1070561B - Use of specific dose of fondaparinux sodium for the treatment of acs - Google Patents

Use of specific dose of fondaparinux sodium for the treatment of acs Download PDF

Info

Publication number
HK1070561B
HK1070561B HK05101101.9A HK05101101A HK1070561B HK 1070561 B HK1070561 B HK 1070561B HK 05101101 A HK05101101 A HK 05101101A HK 1070561 B HK1070561 B HK 1070561B
Authority
HK
Hong Kong
Prior art keywords
acs
treatment
dose
fondaparinux sodium
bleeding
Prior art date
Application number
HK05101101.9A
Other languages
German (de)
English (en)
Chinese (zh)
Other versions
HK1070561A1 (en
Inventor
Anthonie Wilhelmus A. Lensing
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Priority claimed from PCT/EP2002/012482 external-priority patent/WO2003041722A1/fr
Publication of HK1070561A1 publication Critical patent/HK1070561A1/en
Publication of HK1070561B publication Critical patent/HK1070561B/en

Links

Claims (3)

  1. Utilisation d'une dose de 2,5 mg du pentasaccharide méthyl-O-(2-désoxy-2-sulfoamino-6-O-sulfo-α-D-glucopyranosyl)-(1→4) -O- (β-D-glucopyranosyl-acide uronique)-(1→4) -O-(2-désoxy-2-sulfoamino-3,6-di-O-sulfo-α-D-glucopyranosyl)-(1→4)-O-(2-O-sulfo-α-L-idopyranosyl-acide uronique)-(1→4)-2-désoxy-2-sulfoamino-6-O-sulfo-α-D-glucopyranoside ou d'un de ses sels pharmaceutiquement acceptables pour la préparation d'un médicament destiné au traitement de syndromes coronariens aigus (ACS).
  2. Utilisation suivant la revendication 1, dans laquelle le pentasaccharide est sous forme de son sel décasodique.
  3. Utilisation suivant la revendication 1 ou 2 pour le traitement de ACS sans élévation du segment ST.
HK05101101.9A 2001-11-13 2002-11-07 Use of specific dose of fondaparinux sodium for the treatment of acs HK1070561B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01204323 2001-11-13
EP01204323 2001-11-13
PCT/EP2002/012482 WO2003041722A1 (fr) 2001-11-13 2002-11-07 Utilisation d'une dose specifique de fondaparinux sodique pour traiter des syndromes coronariens aigus

Publications (2)

Publication Number Publication Date
HK1070561A1 HK1070561A1 (en) 2005-06-24
HK1070561B true HK1070561B (en) 2007-12-28

Family

ID=

Similar Documents

Publication Publication Date Title
Rentrop et al. Serial angiographic assessment of coronary artery obstruction and collateral flow in acute myocardial infarction. Report from the second Mount Sinai-New York University Reperfusion Trial.
Verstraete et al. Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: initial patency and influence of maintained infusion on reocclusion rate
DK175978B1 (da) Anvendelse af AICA-ribosid eller AICA-ribotid til fremstilling af et farmaceutisk præparat til behandling af hjerteanfald eller salgtilfælde i patienter, som lider af atherosklerose
Weaver et al. New recombinant glycosylated prourokinase for treatment of patients with acute myocardial infarction
Bonnier et al. Comparison of intravenous anisoylated plasminogen streptokinase activator complex and intracoronary streptokinase in acute myocardial infarction
EP1446131B1 (fr) Utilisation d'une dose specifique de fondaparinux sodique pour traiter des syndromes coronariens aigus
Bär et al. Comparison of saruplase and alteplase in acute myocardial infarction
AU2002351915A1 (en) Uso of specific dose of fondaparinux sodium for the treatment of ACS
JP2005509007A6 (ja) Ａｃｓの治療のためのフォンダパリヌックスナトリウムの特定投与量の使用
HK1070561B (en) Use of specific dose of fondaparinux sodium for the treatment of acs
von Essen et al. HBW 023 (recombinant hirudin) for the acceleration of thrombolysis and prevention of coronary reocclusion in acute myocardial infarction: results of a dose-finding study (HIT-II) by the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte
Molhoek et al. Angiographic dose-finding study with r-hirudin (HBW 023) for the improvement of thrombolytic therapy with streptokinase (HIT-SK) Interim results
CHEN et al. Recent advances in antithrombin therapy for acute coronary syndromes
Chew Bivalirudin, a bivalent, thrombin specific anticoagulant as an alternative to heparin in interventional procedures
Jian-Feng et al. The effect of calcitonin gene-related peptide on arrhythmia caused by adenosine diphosphate and desacetyldigilanide-C in rats
Croydon Preliminary safety and tolerance data obtained in the comparative study of anisoylated plasminogen streptokinase activator complex versus heparin
Briguori et al. Thrombocytopenia and purpura-like lesions associated with clopidogrel
JPS6354690B2 (fr)
Lichstein et al. Epoprostenol (prostacyclin) in unstable angina
PL207144B1 (pl) Dawka pentasacharydu metylo-O-(2,3,4-tri-O-metylo-6-O-sulfo-α-D-glukopiranozylo)-(1→4)-O-(2,3-di-O-metylo-β-D-glukopiranozylo kwas uronowy)-(1→4)-O-(2,3,6-tri-O-sulfo-α-D-glukopiranozylo)-(1→4)-O-(2,3-di-O-metylo-α-L-idopiranozylo kwas uronowy)-(1→4)-2,3,6-tri-O-sulfo-α-D-glukopiranozydu i jej zastosowanie
Waldo et al. Verapamil therapy in the treatment of supraventricular arrhythmias following open heart surgery
Timmis et al. An interim report of a double-blind placebo-controlled recanalisation study of anisoylated plasminogen streptokinase activator complex in acute myocardial infarction
Kusz et al. Ranolazine-a new drug for patients with recurrentantiarrhythmic therapy
Kusz et al. Ranolazyna—nowy lek w nawracających opornych na leczenie arytmiach komorowych?
Dalteparin Thromhoprophylaxis in Hip Fracture Surgery: A Pilot Study Gomparing